Last updated: August 3, 2020

1

What is hPG80?

Progastrin is an intracellular protein that is, or not, maturated into gastrin. 

Non Pathologic Condition

Progastrin is not found in the blood 
of healthy people.

When progastrin is maturated into gastrin, it is released from the cells. 

When gastrin is produced by the G cells of the stomach antrum, it plays its role to control acidic secretions during digestion.

Pathologic Condition

hPG80 (circulating progastrin) is detected in the blood of cancer patients.

When progastrin is not maturated into gastrin, it is released from the cells as such and named hPG80.

This only happens in tumor cells, whatever the tumor cell: progastrin becomes a circulating protein, hPG80, which can be detected in the blood of cancer patients. 

The ROCHE laboratory markets a test for the detection of Progastrin-releasing peptide (Pro-GRP) to differentiate between 2 types of lung cancer. hPG80 (Progastrin) and Progastrin-releasing peptide (Pro-GRP) are two completely different proteins even though they share the  word "Progastrin / Pro-Gastrin” with the same phonetics.  

 

2

hPG80 in cancer evolution

The biomarker hPG80 is present in the tumor / bloodstream of cancer patients at all stages of tumor progression, from primary tumor to metastasis.

Example of CRC

 

3

Involvement of the Wnt pathway in tumorigenesis

3.1

Activation – Non activation of  Wnt/ß-Catenin Pathway

The Wnt signaling pathway is an evolutionarily conserved signal transduction pathway that regulates a wide range of cellular functions during development and adulthood. It controls multiple aspects of development, including cell proliferation, cell fate determination, apoptosis, cell migration and cell polarity during development and stem cell maintenance in adults. Inappropriate activation of the Wnt pathway is also a major factor in human oncogenesis (Ng et al, Cells, 2019).

Normal Cell: ON

Normal Cell: OFF

3.2

An early event in cancer development

Chronic activation of the Wnt/ß-catenin pathway is a central mechanism in cancer biology that is implicated in:

  • Induction of cellular proliferation and blocking of differentiation leading to primary tumor growth,

  • Induction of epithelial mesenchymal transition (EMT) leading to metastasis formation, 

  • Regulation of cancer stem cell pathways leading to chemoresistance and relapse.

3.3

hPG80: the gene GAST coding for hPG80 
is a direct Wnt/ß-catenin Target Gene

In normal cells: Tunable (On/Off) activation of the Wnt/ß-catenin target genes. 


In cancer cells: Constitutively activated Wnt/ß-catenin pathway leads to continuous expression of the gene GAST coding for hPG80 and secretion of hPG80.

Tumor Cell: always ON

 

4

hPG80, the biomarker of tumoral activity

Cancer stem cells (CSCs) play an important role in tumor initiation and progression.

CSCs are cells within a tumor that possess the capacity to self-renew, to give rise to the heterogeneous lineages, to be resistant to standard therapy and to initiate tumor recurrence and metastasis (Curtin el al, Oncotarget 2010).

CSCs need hPG80 for their survival (Giraud et al, Cancer Research, 2016; Prieur et al, Clin Cancer Research, 2017).

CSCs secrete 100 to 1000 more of hPG80 than non-CSC cancer cells (Prieur et al, Clin Cancer Research, 2017).

 

Secreted hPG80 maintains the stemness of CSCs (Prieur et al, Clin Cancer Research, 2017).

Neutralization of secreted hPG80 by a therapeutic antibody decreases CSCs frequency, metastatic seeding, increases chemosensitivity and delays relapses (Prieur et al, Clin Cancer Research, 2017).

 

Learn more... 

about

hPG80

Performances
 

IT'S TIME TO CONTROL CANCER

It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detects the presence but also the activity of the tumor.

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg

MAINS LOCATIONS AND OFFICES:

  • LUXEMBURG

  • SWITZERLAND

  • FRANCE

  • UNITED ARAB EMIRATES

  • UNITED STATES OF AMERICA

MAINS COMPANIES:

  • ECS PROGASTRIN

  • ECS PROGASTRIN LAB

  • PROGASTRINE ET CANCERS

  • EUROBIODEV

  • PROGASTRIN MANUFACTURING

Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2020 ECS-Progastrin ® . All rights reserved